Provider | Scheme year | Sample type | 1stEGFR Variant | VAF variant 1 (in %) | 2nd (and 3rd) EGFR variant | VAF variant 2 (in %) | # participants | # correct (%) | # false-negative (%) | # wrong mutation (%) | # technical failure (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
ESP | 2013 | Cell line | c.2369C>T p.(Thr790Met) | 25b | c.2573T>G p.(Leu858Arg) | 25b | 107 | 65 (70.7) | 27 (29.3) | 0 (0.0) | 15 (14.0) |
2014 | Cell line | c.2369C>T p.(Thr790Met) | 45b | c.2573T>G p.(Leu858Arg) | 45b | 144 | 133 (92.4) | 10 (6.9) | 1 (0.7) | 0 (0.0) | |
Cell line | 25b | c.2573T>G p.(Leu858Arg) | 25b | 144 | 135 (93.8) | 8 (5.6) | 1 (0.7) | 0 (0.0) | |||
Resection | 27 | c.2155G>A p.(Gly719Ser) + c.2327G>A p.(Arg776His) | 79 76 | 144 | 77 (53.5) | 66 (45.8) | 1 (0.7) | 0 (0.0) | |||
2015 | Resection | c.2369C>T p.(Thr790Met) | 15 | c.2573T>G p.(Leu858Arg) | 89 | 114 | 92 (84.4) | 16 (14.7) | 1 (0.9) | 5 (4.4) | |
2016 | Resection | c.2369C>T p.(Thr790Met) | 19 | c.2235_2249del p.(Glu746_Ala750del) | 30 | 43 | 42 (97.7) | 1 (2.3) | 0 (0.0) | 0 (0.0) | |
2017 (Jun.)a | Resection | c.2369C>T p.(Thr790Met) | 18 | c.2573T>G p.(Leu858Arg) + c.2389T>A p.(Cys797Ser) | 35 18 | 107 | 87 (81.3) | 20 (18.7) | 0 (0.0) | 0 (0.0) | |
2017 (Oct.)a | Cell line | c.2369C>T p.(Thr790Met) | 20 | / | / | 102 | 97 (99.0) | 1 (1.0) | 0 (0.0) | 4 (3.9) | |
2018 | Resection | c.2369C>T p.(Thr790Met) | 22 | c.2573T>G p.(Leu858Arg) | 22 | 101 | 101 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Resection | 43 | c.2236_2248delinsCAAC p.(E746_A750delinsQP) | 80 | 101 | 101 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
Gen&Tiss | 2014 | Cell line | c.2369C>T p.(Thr790Met) | 17 | / | / | 43 | 39 (92.8) | 2 (4.8) | 1 (2.4) | 1 (2.3) |
2016 | Cell line | c.2369C>T p.(Thr790Met) | 22 | c.2573T>G p.(Leu858Arg) | 18 | 40 | 39 (100.0) | 0 (0.0) | 0 (0.0) | 1 (2.5) |